微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 70.97% | -4.99% | -1.61% | 32/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 72.13% | -1.95% | -5.12% | 31/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 76.02% | 3.08% | 1.04% | 25/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 75.24% | 3.78% | 0.74% | 26/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 74.69% | 5.53% | 1.54% | 24/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 73.56% | 1% | -0.26% | 27/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 73.75% | 0.88% | 1.73% | 27/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 72.5% | -1.69% | 2.43% | 28/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 70.78% | -3.48% | -2.82% | 29/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 72.83% | -4.5% | -0.38% | 31/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 73.11% | -4.34% | -0.86% | 31/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 73.75% | -2.76% | 0.57% | 31/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 73.33% | -2.68% | -3.84% | 30/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 76.26% | -1.22% | -0.22% | 31/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 76.43% | 1.07% | 0.77% | 31/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 75.84% | 0.06% | 0.66% | 30/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 75.34% | -3.29% | -2.4% | 31/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 77.2% | 2.19% | 2.09% | 31/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 75.62% | -0.68% | -0.23% | 26/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 75.79% | 0.15% | -2.71% | 27/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 77.9% | 2.36% | 3.13% | 19/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 75.54% | 20.65% | -0.78% | 28/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 76.13% | 25.77% | 0.6% | 23/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 75.68% | 28.01% | -0.56% | 21/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 76.11% | 32.86% | 21.55% | 22/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 62.62% | 11.52% | 3.44% | 52/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 60.53% | 11.47% | 2.39% | 45/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 59.12% | 11.47% | 3.2% | 52/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 57.29% | 6.26% | 2.03% | 46/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 56.15% | 17.05% | 3.38% | 64/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 54.31% | 8.36% | 2.4% | 52/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 53.04% | 5.97% | -1.62% | 53/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 53.91% | 4.83% | 12.39% | 50/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 47.97% | 4.07% | -4.29% | 68/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 50.12% | 11.36% | 0.14% | 45/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 50.05% | 16.77% | -2.68% | 45/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 51.43% | 16.01% | 11.58% | 35/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 46.09% | 10.04% | 2.41% | 56/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 45.01% | 9.78% | 5.01% | 36/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 42.86% | 2.91% | -3.32% | 44/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 44.33% | 5.87% | 5.84% | 34/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |